FIELD: pharmaceuticals.
SUBSTANCE: invention relates to pyrimidine and a derivative of a five-membered nitrogen-containing heterocycle by the general formula (I), a method for production thereof, a pharmaceutical composition containing the derivative, an application thereof as an SHP2 inhibitor for application in the prevention and/or treatment of tumours or cancer.
EFFECT: possibility of creating a composition applicable in treating cancer.
12 cl, 50 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN TYROSIN PHOSPHATASE INHIBITORS | 2020 |
|
RU2799449C2 |
| N2-(2-PHENYL)-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND USE THEREOF AS MPS1 INHIBITOR | 2015 |
|
RU2693460C2 |
| COMPOUNDS WITH SPIRO AND AROMATIC RINGS AND APPLICATION THEREOF | 2019 |
|
RU2781100C1 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
| BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2018 |
|
RU2776846C2 |
| CYCLIC CYANOENONE DERIVATIVES AS KEAP1 MODULATORS | 2021 |
|
RU2822828C1 |
| INFLUENZA VIRUS REPLICATION INHIBITORS, METHODS OF APPLICATION AND USING | 2016 |
|
RU2737190C2 |
| COMPOUNDS AND COMPOSITIONS FOR SUPPRESSING SHP2 ACTIVITY | 2017 |
|
RU2744988C2 |
| HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | 2018 |
|
RU2726631C1 |
